Channel Therapeutics Corporation
CHRO
$1.12
$0.032.75%
AMEX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -13.69% | 4.34% | 30.86% | 36.56% | -184.11% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | 638.83% | -- | -100.00% | 854.17% | -136.62% |
| Total Other Non-Cash Items | 243.75% | -66.38% | 56.87% | -90.91% | 1,387.34% |
| Change in Net Operating Assets | -51.93% | 182.46% | -400.40% | -160.24% | -25.36% |
| Cash from Operations | -276.78% | 93.97% | -48.22% | -458.27% | -38.72% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | 82.86% | -156.53% | -- | -- | -11.66% |
| Total Debt Repaid | -- | -- | 100.00% | -- | -- |
| Issuance of Common Stock | -- | -- | -100.00% | 2,238.29% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 200.00% | -- | 100.00% | -- | -- |
| Cash from Financing | 92.68% | -161.25% | -71.98% | 1,216.38% | 117.26% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 35.53% | 15.74% | -137.16% | 4,891.58% | 224.53% |